Learn more about how TANOVEA-CA1 benefits veterinarians and pet owners.

TANOVEA-CA1 – the first FDA conditionally approved drug for the treatment of lymphoma in dogs – has demonstrated a 77 percent overall response and a 45 percent complete response rate, supporting a reasonable expectation of efficacy in both naïve and relapsed/refractory lymphoma.

Available in all 50 states, TANOVEA-CA1 is an exciting new cancer treatment for dogs that is specifically designed to target and kill canine lymphoma cells. TANOVEA-CA1 is easy to administer, with only five doses for a full treatment, and is generally well-tolerated in clinical studies.

This canine lymphoma treatment is a convenient option for pet owners and clinics. Veterinarians administer TANOVEA-CA1 every three weeks with a simple, 30-minute intravenous infusion.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-475.

 

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. It is a violation of Federal Law to use this product other than as directed in the labeling.

 

Important Safety Information: TANOVEA®-CA1 (rabacfosadine for injection) is not for use in humans and should be kept out of the reach of children. Wear chemotherapy-resistant gloves to prevent contact with feces, urine, vomit, and saliva of treated dogs for five days following treatment. Rabacfosadine is cytotoxic and can cause birth defects and affect female and male fertility. Pregnant and breast-feeding women should not prepare or administer the product. Serious and sometimes fatal respiratory complications, including pulmonary fibrosis have occurred in dogs treated with TANOVEA®-CA1. Do not use in dogs with pulmonary fibrosis, a history of chronic pulmonary disease that could lead to fibrosis, or in breeds with a predisposition to this condition such as West Highland White Terriers. Use with caution in other terrier breeds. Do not use in dogs that are pregnant, lactating, or intended for breeding. Most common adverse reactions included diarrhea, neutropenia, hyporexia, weight loss, and lethargy.  Please see the package insert for full prescribing information.